The figure shows a change in the number of our patients since we were established (between FY2004 and FY2019). The number of our outpatients has been on a steady increase. The daily average of our outpatients increased from 10.9 in FY2004 to 73.8 in FY2019. Meanwhile, regarding our inpatients, the total number of discharged patients per year has been on a steady increase as well, from 50 in FY2004 to around 260 to 300 since FY2011. As for other our clinical accomplishments in FY2019, the daily average of inpatients (the number of inpatients staying at our facility) was 19.1. The average period of hospitalization was 25.3 days.
We mainly cover various rheumatic diseases such as rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis (scleroderma), dermatomyositis/polymyositis, mixed connective-tissue disease, Sjögren's syndrome, polymyalgia rheumatica syndrome, vasculitis syndrome, Behçet disease. We provide outpatient consultation and hospitalized care. We treat rheumatoid arthritis proactively using biological products and/or molecular targeted drugs such as JAK inhibitor in addition to anti-rheumatoid drugs. To treat other rheumatic diseases, we often use high dose steroid and/or immunosuppressant, so that we are paying attention to infectious complications following compromised conditions. We are striving to provide the most advanced medicine safely to our patients.